March 14 (Reuters) - The U.S. Food and Drug

Administration said on Friday that supply interruptions of

hemodialysis bloodlines, a key component in dialysis devices,

are expected to continue through early fall 2025 due to recent

supplier issues.

Hemodialysis bloodlines are sets of tubes that connect a

patient's bloodstream to the dialysis device during treatment.

The health agency's statement follows a January announcement

from medical device maker B. Braun, which cited supply and labor

constraints disrupting production of some hemodialysis

bloodlines, with inventory expected to run out by January 20.

The FDA recommended health care providers conserve the

use of the bloodlines when possible, adding that it is

monitoring the situation and is working with manufacturers and

dialysis providers to mitigate impact on patients.